ADG116
ADG116 is a fully human anti-CTLA-4 NEObody. The dynamic interface of ADG116 enabled its species crossreactivity with human, cynomolgus monkey, and mouse CTLA-4 for robust preclinical studies. Also its dynamic engagement on a unique epitope of CTLA-4 to trigger a novel MOA by softer ligand blocking and stronger regulatory T-cell depletion via strong ADCC.
ADG116 is in phase 1b/2 development in patients with advanced metastatic solid tumors and exploring doses which are significantly higher than the level for a commercially available CTLA-4 therapy in specific indications.